Medical news
of the North Caucasus
Scientific journal
Mass media registration certificate dated December 7, 2006.
Series ПИ #ФС 77-26521.
Federal service for surveillance over non-violation of the legislation in the sphere of mass communications and protection of cultural heritage.
ISSN 2073-8137

Site search

Correspondence address
310 Mira Street, Stavropol, Russia, 355017

+7 865 2352511, +7 865 2353229.


Intracellular adhesion molecules and histological pattern in chronic viral liver diseases

[Original research] [Internal diseases]
Pavel Koroy; Irina Mukhoramova; Alexandr Yagoda;

Serum levels of intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) were studied in 50 patients with chronic viral liver diseases in view of hepatic histo- logical changes.

The patients with chronic viral hepatitis demon- strated higher levels of intercellular adhesion molecule-1 in the blood while an increase in the serum levels of the two adhesion molecules was observed in the cases with liver cirrhosis.

The blood levels of ICAM-1 and VCAM-1 under chronic viral liver diseases increases along with a growing intensity of hepatic steatosis, inflammation and fibrosis. The association of morphological changes in the liver with the mediators of intercellular interactions proves their important role in occurrence and development of chronic viral liver diseases.


1. Abdalla A., Sheesha A. A., Shokeir M. et al. Serum intercellular adhesion molecule-1 in children with chronic liver disease: relationship to disease activity. Dig. Dis. Sci. 2002;47(6):1206-1208.
2. Abdallah N., Morsi M., Hamed N., Abdel Aziz H. Evaluation of prognostic value of cell adhesion molecules in chronic hepatitis C therapy. J. Venom. Anim. Toxins. Incl. Trop. Dis. 2010;16(3):442-448.
3. Bruno C. M., Sciacca C., Cilio D. et al. Circulating adhesion molecules in patients with virusrelated chronic diseases of the liver. World. J. Gastroenterol. 2005;11(29):4566-4569.
4. Castera L., Pawlotsky J.-M. Noninvasive diagnosis of liver fibrosis in patients with chronic hepatitis C. Med. Gen. Med. 2005. – Vol. 7 (4). – P. 39-45.
5. De Castro, I.F. Hepatitis C virus infection is associated with endothelial dysfunction in HIV/hepatitis C virus coinfected patients / I.F. De Castro, D. Micheloud, J. Berenguer [et al.] // AIDS. – 2010;24(13):2059-2067.
6. El-Shazly M., Yehia Aly N., El-Shimi I. et al. Soluble in tercellular adhesion molecule-1 in sera of patients with chronic hepatitis C. Bull. Alexandria. Faculty. Med. 2007;43(4):25-31.
7. Iredale J. P. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J. Clin. Invest. 2007;117:539-548.
8. Kawasuji A., Hasegawa M., Horikawa M. et al. L-selectin and intercellular adhesion molecule-1 regulate the development of Concanavalin A-induced liver injury. J. Leukoc. Biol. 2006;79(4):696-705.
9. Kukla M., Zwirska-Korczala K., Gabriel A. et al. Soluble platelet-endothelial cell adhesion molecule-1 and soluble vascular cell adhesion molecule-1: role in pathogenesis and diagnosis of chronic hepatitis C and association with response to antiviral therapy. Therap. Adv. Gastroenterol. 2009;2(2):79-90.
10. Li X., Klintman D., Weitz-Schmidt G. et al. Lymphocyte function antigen-1 mediates leukocyte adhesion and subsequent liver damage in endotoxemic mice. Br. J. Pharmacol. 2004;141(4):709-716.
11. Lv P., Luo H. S., Zhou X. P. et al. Reversal effect of thalidomide on established hepatic cirrhosis in rats via inhibition of nuclear factor-kappaB/inhibitor of nuclear fac- tor-kappaB pathway. Arch. Med. Res. 2007;38(1):15-27.
12. Lv P., Paul S. C., Xiao Y. et al. Effects of thalidomide on the expression of adhesion molecules in rat liver cirrhosis. Mediators. Inflamm. 2006;2006(4):932-953.
13. Maeda K., Yoshida K., Ichimiya I., Suzuki M. Dexameth- asone inhibits tumor necrosis factor--induced cytokine secretion from spiral ligament fibrocytes. Hearing Research. 2005;202(1-2):154-160.
14. Paul S. C., Lv P., Xiao Y. et al. Thalidomide in rat liver cirrhosis: blockade of tumor necrosis factor-alpha via inhibition of degradation of an inhibitor of nuclear factor-kappaB. Pathobiology. 2006;73(2):82-92.
15. Pinzani M., Rombouts K. Liver fibrosis: from the bench to clinical targets. Dig. Liver. Dis. 2004;36(4):231-242.
16. Pinzani M., Rombouts K., Colagrande S. Fibrosis in chronic liver diseases: diagnosis and management. J. Hepatol. 2005;42:22-36.
17. Pockros P. J. Noninvasive markers of fibrosis in chronic hepatitis patients. J. Clin. Gastroenterol. 2006;40(6):461-463.
18. Rachwal A. W., Brigstock D. R. Connective tissue growth factor in hepatic fibrosis. Hepatol. Res. 2003;26(1):1-9.
19. Rockey D. C. Antifibrotic therapy in chronic liver dis- ease. Clin. Gastroenterol. Hepatol. 2005;3(2):95-107.
20. Rui-dan Z., Yayong S., Yan-hui L. et al. Alteration of in tercellular adhesion molecule-1 (ICAM-1) expression in the liver and serum level of HBV DNA in chronic hepatitis B patients after interferon treatment. African. J. Microbiol. Res. 2011;5(10):1211-1214.
21. Woo C.-H., Lim J.-H., Kim J.-H. VCAM-1 upregulation via PKC-p38 kinase-linked cascade mediates the TNF--induced leukocyte adhesion and emigration in the lung airway epithelium. Am. J. Physiol. – Lung Cell. Molecular Physiol. 2005;288(2):307–316.

Keywords: chronic viral hepatitis, liver cirrhosis, intercellular adhesion molecule-1, vascular cell adhesion molecule-1

Stavropol State Medical Academy
Pyatigorsk State Research Institute of Balneotherapeutics
Pyatigorsk State Pharmaceutical Academy